Casirivimab/imdevimab and bamlanivimab/etesevimab were granted emergency use authorization for the treatment of mild to moderate COVID-19. Until the national supply of these monoclonal antibodies (mAbs) is sufficient, the Iowa Department of Health and Human Services and the United States government will help facilitate allocation across Iowa.
Find a COVID-19 Monoclonal Antibody Provider
HHS mAb Site Locator NICA mAb Site Locator
Request COVID-19 Monoclonal Antibodies
Casirivimab/imdevimab and bamlanivimab/etesevimab are available at no cost to healthcare providers. Healthcare providers can submit a request to the Iowa Department of Health and Human Services. This request will be added to a list of eligible recipients for monoclonal antibody products for future allocations. Eligibility is not a guarentee for receiving future allocations of monoclonal antibody products.
Additional information on the distribution process can be found here.
General Resources
- Therapeutics Brief 6.2.23
- Therapeutics Brief 4.14.23
- Therapeutics Brief 1.26.23
- Therapeutics Brief 12.14.22
- Therapeutics Brief 12.1.22
- Therapeutics Brief 11.30.22
- Therapeutics Brief 11.9.22
- HRSA COVID Uninsured Claim
- DHS and IME COVID-19 Vaccines and Monoclonal Antibodies Information Letter
- HHS Combat COVID Website
- National Infusion Center Association COVID-19 Antibody Treatment Resource Center
- NIH Treatment Guidelines
- Vaccine and Monoclonal Antibodies Guidance: See NIH Treatment Guidelines and Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States
- COVID-19 Monoclonal Antibody Therapeutics Digital Toolkit
- IDPH Therapeutic Guidance - Anti-Virals
- IDPH Therapeutic Guidance - mAb
- IDPH Therapeutic Guidance - mAbSp
Bebtelovimab (Eli Lilly)
- Bebtelovimab EUA Letter of Authorization
- Fact Sheet for Healthcare Providers
- Fact Sheet for Patients, Parents and Caregivers
- Frequently Asked Questions for Bebtelovimab
Questions
For questions, please contact Combat COVID Monoclonal Antibodies Call Center at 877-332-6585.